CELC - Celcuity Inc.
About Celcuity Inc. (https://www.celcuity.com)
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer | 1962 | $945,218 USD |
| Lance G. Laing | Co-Founder, Chief Science Officer, Vice President, Secretary & Director | 1962 | $673,781 USD |
| Vicky Hahne | Chief Financial Officer | 1966 | $598,079 USD |
| Brent Eilefson | General Counsel | – | – |
| Eldon C. Mayer | Chief Commercial Officer | 1961 | – |
| Igor Gorbatchevsky | Chief Medical Officer | – | – |
| Jodi Sievers | Head of Investor Relations & Corporate Communications | – | – |
| Sheri Smith | Acting Head of Clinical Operations | – | – |